Treatment of deep venous thrombosis with low-molecular-weight heparin during pregnancy

Thrombosis Research

Volumn 106, Issue 1, 2002, Pages 13-17

  Ulander, Veli Matti ^a   Stenqvist, Pauliina ^a   Kaaja, Risto ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Dalteparin; Deep venous thrombosis; Low molecular weight heparin; Pregnancy; Treatment

Indexed keywords

DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DELIVERY; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; FEMALE; HUMAN; PREGNANCY; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; TREATMENT OUTCOME; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG SCREENING; PREGNANCY COMPLICATION; PROSPECTIVE STUDY; VEIN THROMBOSIS;

ADULT; DALTEPARIN; DRUG EVALUATION; FEMALE; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PROSPECTIVE STUDIES; RECURRENCE; VENOUS THROMBOSIS;

EID: 0036544771     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00074-9     Document Type: Article

References (21)

1. Thromboembolic disease in pregnancy
2. Epidemiology, risk factors and prophylaxis of venous thromboembolism in obstetrics and gynaecology
3. Low molecular weight (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound
4. Absence of transplacental passage of Fragmin during the second and third trimester of pregnancy
5. Placental transport of heparin
6. Thrombosis prophylaxis in obstetrics and gynaecology
7. Use of antithrombotic agents during pregnancy
8. Venous thromboembolism during pregnancy
9. Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy
10. A meta-analysis comparing low molecular weight heparin to unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency
11. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: A meta-analysis of randomised, controlled trials
12. Mutation in blood coagulation factor V associated with resistance to activated protein C
13. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
14. Treatment of venous thrombo-embolism
15. Use of antithrombotic agents during pregnancy
16. Coagulation activation markers do not correlate with the clinical risk of thrombosis in pregnant women
17. Epidemiology, risk factors and prophylaxis of venous thromboembolism in obstetrics and gynaecology
18. Thrombosis in pregnancy: Maternal and fetal issues
19. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
20. Thrombophilia, thrombosis and pregnancy
21. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin